Report ID: SQMIG35I2114
Psychedelic Drugs Market Size, Share, Growth Analysis, By Source (Synthetic, Natural), By Type (Empathogens, Dissociatives), By Drug (Gamma-Hydroxybutyric Acid (GHB), Ketamine), By Application (Narcolepsy, Treatment-Resistant Depression), By Route of Administration, By End-User, By Distribution Channel, By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2114 |
Region:
Global |
Published Date: December, 2024
Pages:
242
|
Tables:
200 |
Figures:
80
Psychedelic Drugs Market Regional Insights
North America is expected to continue to dominate the global psychedelic drugs market during the forecast period. The FDA's recognition of advanced drug fusion portfolios obtained from psychedelic drugs has aided the growth of the North American market. Furthermore, the presence of key market players in this region, as well as increased investment in research and development activities, are supporting market growth. The European Union is the second-largest market after North America in terms of psychedelic drug market share.
The Asia Pacific market for psychedelic drugs is also expected to grow slowly. The sale of FDA-approved psychedelic drugs in the country has increased research activities. The increasing presence of key pharmaceutical players in the country for oncology-related treatment and ketamine psychedelic drugs is expected to pave the way for the development of psychedelic drugs for medicinal purposes.
Psychedelic Drugs Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
